Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Lung Cancer

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 75 articles: HTML format Text format

Single Articles

October 2018
1. XIE Y, Lu W, Wang S, Tang X, et al
   Validation of the 12-gene predictive signature for Adjuvant Chemotherapy Response in Lung Cancer.
   Clin Cancer Res. 2018 Oct 4. pii: 1078-0432.CCR-17-2543.
   PubMed     Text format     Abstract available
   
   
   September 2018
2. DAGOGO-JACK I, Martinez P, Yeap BY, Ambrogio C, et al
   Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-Mutant Lung Cancer.
   Clin Cancer Res. 2018 Sep 17. pii: 1078-0432.CCR-18-2062.
   PubMed     Text format     Abstract available
   
   
   
3. LO RUSSO G, Moro M, Sommariva M, Cancila V, et al
   Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-Small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.
   Clin Cancer Res. 2018 Sep 11. pii: 1078-0432.CCR-18-1390.
   PubMed     Text format     Abstract available
   
   
   
4. PETERS S, Stahel RA, Bubendorf L, Bonomi P, et al
   Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety and Biomarkers.
   Clin Cancer Res. 2018 Sep 11. pii: 1078-0432.CCR-18-1590.
   PubMed     Text format     Abstract available
   
   
   
5. CORREDOR G, Wang X, Zhou Y, Lu C, et al
   Spatial architecture and arrangement of tumor-infiltrating lymphocytes for predicting likelihood of recurrence in early-stage non-small cell lung cancer.
   Clin Cancer Res. 2018 Sep 10. pii: 1078-0432.CCR-18-2013.
   PubMed     Text format     Abstract available
   
   
   August 2018
6. RICHARD C, Fumet JD, Chevrier S, Derangere V, et al
   Exome analysis reveals genomic markers associated with better efficacy of nivolumab in lung cancer patients.
   Clin Cancer Res. 2018 Aug 28. pii: 1078-0432.CCR-18-1940.
   PubMed     Text format     Abstract available
   
   
   
7. PINE SR
   Rethinking gamma-secretase inhibitors for treatment of non-small cell lung cancer: Is Notch the target?
   Clin Cancer Res. 2018 Aug 13. pii: 1078-0432.CCR-18-1635.
   PubMed     Text format     Abstract available
   
   
   
8. SONG KA, Hosono Y, Turner C, Jacob S, et al
   Increased synthesis of MCL-1 protein underlies initial survival of EGFR mutant lung cancer to EGFR inhibitors and provides a novel drug target.
   Clin Cancer Res. 2018 Aug 7. pii: 1078-0432.CCR-18-0304.
   PubMed     Text format     Abstract available
   
   
   
9. KIM ES, Kelly K, Paz-Ares L, Garrido P, et al
   Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase 1b Study.
   Clin Cancer Res. 2018 Aug 6. pii: 1078-0432.CCR-18-0651.
   PubMed     Text format     Abstract available
   
   
   
10. BAHCALL M, Awad MM, Sholl LM, Wilson FH, et al
    Amplification of wild type KRAS imparts resistance to crizotinib in MET exon 14 mutant non-small cell lung cancer.
    Clin Cancer Res. 2018 Aug 2. pii: 1078-0432.CCR-18-0876.
    PubMed     Text format     Abstract available
    
    
    
11. WANG Y, Li N, Jiang W, Deng W, et al
    Mutant LKB1 confers enhanced radiosensitization in combination with trametinib in KRAS-mutant non-small cell lung cancer.
    Clin Cancer Res. 2018 Aug 1. pii: 1078-0432.CCR-18-1489.
    PubMed     Text format     Abstract available
    
    
    July 2018
12. PONATH P, Menezes DL, Pan C, Chen B, et al
    A novel, fully human anti-fucosyl-GM1 antibody demonstrates potent in vitro and in vivo antitumor activity in preclinical models of small cell lung cancer.
    Clin Cancer Res. 2018 Jul 18. pii: 1078-0432.CCR-18-0018.
    PubMed     Text format     Abstract available
    
    
    
13. AKIBA T, Morikawa T, Odaka M, Nakada T, et al
    Vitamin D supplementation and survival of patients with non-small-cell lung cancer: A randomized, double-blind, placebo-controlled trial.
    Clin Cancer Res. 2018 Jul 17. pii: 1078-0432.CCR-18-0483.
    PubMed     Text format     Abstract available
    
    
    
14. ROMANIELLO D, Mazzeo L, Mancini M, Marrocco I, et al
    A Combination Of Approved Antibodies Overcomes Resistance Of Lung Cancer To Osimertinib By Blocking Bypass Pathways.
    Clin Cancer Res. 2018 Jul 2. pii: 1078-0432.CCR-18-0450.
    PubMed     Text format     Abstract available
    
    
    June 2018
15. LI S, Liu S, Deng J, Akbay EA, et al
    Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS G12C-Driven Mouse Model of Lung Cancer.
    Clin Cancer Res. 2018 Jun 26. pii: 1078-0432.CCR-17-3438.
    PubMed     Text format     Abstract available
    
    
    
16. KO EC, Raben D, Formenti SC
    The Integration of Radiotherapy With Immunotherapy for the Treatment of Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2018 Jun 26. pii: 1078-0432.CCR-17-3620.
    PubMed     Text format     Abstract available
    
    
    
17. LAIRD JH, Lok BH, Ma J, Bell A, et al
    Talazoparib is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts.
    Clin Cancer Res. 2018 Jun 26. pii: 1078-0432.CCR-18-0401.
    PubMed     Text format     Abstract available
    
    
    
18. LALLO A, Frese KK, Morrow C, Szczepaniak Sloane R, et al
    The combination of the PARP inhibitor olaparib and the Wee1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer.
    Clin Cancer Res. 2018 Jun 25. pii: 1078-0432.CCR-17-2805.
    PubMed     Text format     Abstract available
    
    
    
19. SAIGI M, Alburquerque-Bejar JJ, McLEER-Florin A, Pereira C, et al
    MET-oncogenic and JAK2-inactivating alterations are independent factors that affect regulation of PD-L1 expression in lung cancer.
    Clin Cancer Res. 2018 Jun 13. pii: 1078-0432.CCR-18-0267.
    PubMed     Text format     Abstract available
    
    
    May 2018
20. BAUML J, Levy B
    Clonal Hematopoiesis: A new layer in the liquid biopsy story in lung cancer.
    Clin Cancer Res. 2018 May 10. pii: 1078-0432.CCR-18-0969.
    PubMed     Text format     Abstract available
    
    
    
21. HIGGS BW, Morehouse C, Streicher KL, Brohawn P, et al
    Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small-Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab.
    Clin Cancer Res. 2018 May 1. pii: 1078-0432.CCR-17-3451.
    PubMed     Text format     Abstract available
    
    
    
22. NAZ S, Sowers AL, Choudhuri R, Wissler MF, et al
    Abemaciclib, a Selective CDK4/6 Inhibitor Enhances the Radiosensitivity of Non-Small Cell Lung Cancer in vitro and in vivo.
    Clin Cancer Res. 2018 May 1. pii: 1078-0432.CCR-17-3575.
    PubMed     Text format     Abstract available
    
    
    April 2018
23. CLARET L, Jin JY, Ferte C, Winter H, et al
    A model of overall survival predicts treatment outcomes with atezolizumab vs chemotherapy in non-small cell lung cancer based on early tumor kinetics.
    Clin Cancer Res. 2018 Apr 23. pii: 1078-0432.CCR-17-3662.
    PubMed     Text format     Abstract available
    
    
    
24. MCCOACH CE, Le A, Gowan K, Jones KL, et al
    Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer.
    Clin Cancer Res. 2018 Apr 10. pii: 1078-0432.CCR-17-2452.
    PubMed     Text format     Abstract available
    
    
    
25. IOMMELLI F, De Rosa V, Terlizzi C, Monti M, et al
    Inositol trisphosphate receptor type 3-mediated enhancement of EGFR and MET co-targeting efficacy in non-small cell lung cancer detected by 18F-fluorothymidine.
    Clin Cancer Res. 2018 Apr 4. pii: 1078-0432.CCR-17-3657.
    PubMed     Text format     Abstract available
    
    
    
26. FRANK R, Scheffler M, Merkelbach-Bruse S, Ihle MA, et al
    Clinical and pathological characteristics of KEAP1- and NFE2L2- mutated non-small cell lung carcinoma (NSCLC).
    Clin Cancer Res. 2018 Apr 3. pii: 1078-0432.CCR-17-3416.
    PubMed     Text format     Abstract available
    
    
    March 2018
27. MCCOACH CE, Blakely CM, Banks KC, Levy BM, et al
    Clinical utility of cell-free DNA for the detection of ALK fusions and genomic mechanisms of ALK inhibitor resistance in non-small cell lung cancer.
    Clin Cancer Res. 2018 Mar 29. pii: 1078-0432.CCR-17-2588.
    PubMed     Text format     Abstract available
    
    
    
28. HORN L, Infante JR, Reckamp KL, Blumenshein GR, et al
    Ensartinib (X-396) in ALK-positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.
    Clin Cancer Res. 2018 Mar 21. pii: 1078-0432.CCR-17-2398.
    PubMed     Text format     Abstract available
    
    
    
29. CASTELLANOS-RIZALDOS E, Grimm DG, Tadigotla V, Hurley J, et al
    Exosome-based Detection of EGFR T790M in Plasma from Non-Small Cell Lung Cancer Patients.
    Clin Cancer Res. 2018 Mar 13. pii: 1078-0432.CCR-17-3369.
    PubMed     Text format     Abstract available
    
    
    
30. YANG Z, Yang N, Ou Q, Xiang Y, et al
    Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients.
    Clin Cancer Res. 2018 Mar 5. pii: 1078-0432.CCR-17-2310.
    PubMed     Text format     Abstract available
    
    
    
31. CAPPUZZO F, Landi L
    HER2 deregulation in lung cancer: right time to adopt an orphan?
    Clin Cancer Res. 2018 Mar 1. pii: 1078-0432.CCR-18-0198.
    PubMed     Text format     Abstract available
    
    
    February 2018
32. BILLATOS E, Vick JL, Lenburg ME, Spira AE, et al
    The Airway Transcriptome as a Biomarker for Early Lung Cancer Detection.
    Clin Cancer Res. 2018 Feb 20. pii: 1078-0432.CCR-16-3187.
    PubMed     Text format     Abstract available
    
    
    
33. TIAN Y, Wang Z, Liu X, Duan J, et al
    Prediction of chemotherapeutic efficacy in non-small cell lung cancer by serum metabolomic profiling.
    Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-2855.
    PubMed     Text format     Abstract available
    
    
    
34. YU J, Wang S, Zhao W, Duan J, et al
    Mechanistic exploration of cancer stem cell marker voltage-dependent calcium channel alpha2delta1 subunit-mediated chemotherapy resistance in small cell lung cancer.
    Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-1932.
    PubMed     Text format     Abstract available
    
    
    
35. MACLEOD AK, Lin, Huang JT, McLaughlin LA, et al
    Identification of novel pathways of osimertinib disposition and potential implications for the outcome of lung cancer therapy.
    Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-3555.
    PubMed     Text format     Abstract available
    
    
    January 2018
36. MCCALL NS, Dicker AP, Lu B
    Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer.
    Clin Cancer Res. 2018 Jan 22. pii: 1078-0432.CCR-17-3269.
    PubMed     Text format     Abstract available
    
    
    
37. KITAJIMA S, Barbie DA
    RASA1/NF1 mutant lung cancer: Racing to the clinic?
    Clin Cancer Res. 2018 Jan 17. pii: 1078-0432.CCR-17-3597.
    PubMed     Text format     Abstract available
    
    
    
38. GOLDBERG SB, Narayan A, Kole AJ, Decker RH, et al
    Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.
    Clin Cancer Res. 2018 Jan 12. pii: 1078-0432.CCR-17-1341.
    PubMed     Text format     Abstract available
    
    
    
39. THANGAVEL C, Boopathi E, Liu Y, McNair C, et al
    Therapeutic Challenge With a CDK 4/6 Inhibitor Induces an RB-dependent SMAC Mediated Apoptotic Response in Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2018 Jan 8. pii: 1078-0432.CCR-17-2074.
    PubMed     Text format     Abstract available
    
    
    
40. LIU S, Li S, Hai J, Wang X, et al
    Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib.
    Clin Cancer Res. 2018 Jan 3. pii: 1078-0432.CCR-17-1875.
    PubMed     Text format     Abstract available
    
    
    December 2017
41. YE M, Zhang Y, Gao H, Xu Y, et al
    Activation of the Aryl Hydrocarbon Receptor Leads to Resistance to EGFR TKIs in Non-Small-Cell Lung Cancer by Activating Src-Mediated Bypass Signaling.
    Clin Cancer Res. 2017 Dec 11. pii: 1078-0432.CCR-17-0396.
    PubMed     Text format     Abstract available
    
    
    
42. AISNER DL, Sholl LM, Berry L, Rossi M, et al
    The Impact of Smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations - the Lung Cancer Mutation Consortium (LCMC2).
    Clin Cancer Res. 2017 Dec 7. pii: 1078-0432.CCR-17-2289.
    PubMed     Text format     Abstract available
    
    
    
43. WANG Q, Zeng F, Sun Y, Qiu Q, et al
    Etk interaction with PFKFB4 modulates chemoresistance of small cell lung cancer by regulating autophagy.
    Clin Cancer Res. 2017 Dec 5. pii: 1078-0432.CCR-17-1475.
    PubMed     Text format     Abstract available
    
    
    
44. VILLARROEL-ESPINDOLA F, Yu X, Datar I, Mani N, et al
    Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in human non-small cell lung cancer.
    Clin Cancer Res. 2017 Dec 4. pii: 1078-0432.CCR-17-2542.
    PubMed     Text format     Abstract available
    
    
    October 2017
45. ARBOUR KC, Jordan EJ, Kim HR, Dienstag J, et al
    Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer.
    Clin Cancer Res. 2017 Oct 31. pii: clincanres.1841.2017.
    PubMed     Text format     Abstract available
    
    
    
46. FABER AC, Song KA, Niederst MJ, Lochmann TL, et al
    Epithelial-to-mesenchymal transition antagonizes response to targeted therapies in lung cancer by suppressing BIM.
    Clin Cancer Res. 2017 Oct 19. pii: clincanres.1577.2017.
    PubMed     Text format     Abstract available
    
    
    
47. FAN Y, Zhu X, Xu Y, Lu X, et al
    Cell-cycle and DNA-damage response pathway is involved in leptomeningeal metastasis of non-small cell lung cancer.
    Clin Cancer Res. 2017 Oct 13. pii: clincanres.1582.2017.
    PubMed     Text format     Abstract available
    
    
    
48. WANG Y, Gudikote J, Giri U, Yan J, et al
    RAD50 expression is associated with poor clinical outcomes after radiotherapy for resected non-small cell lung cancer.
    Clin Cancer Res. 2017 Oct 13. pii: clincanres.1455.2017.
    PubMed     Text format     Abstract available
    
    
    
49. LOHAVANICHBUTR P, Sakoda LC, Amos CI, Arnold SM, et al
    Common TDP1 polymorphisms in relation to survival among small cell lung cancer patients: a multicenter study from the International Lung Cancer Consortium.
    Clin Cancer Res. 2017 Oct 3. pii: clincanres.1401.2017.
    PubMed     Text format     Abstract available
    
    
    September 2017
50. HU X, Liu T, Wu X, Chen T, et al
    Downregulation of DNMT3A by miR-708-5p inhibits lung cancer stem cell-like phenotypes through repressing Wnt/beta-catenin signaling.
    Clin Cancer Res. 2017 Sep 28. pii: clincanres.1169.2017.
    PubMed     Text format     Abstract available
    
    
    
51. YI JS, Ready N, Healy P, Dumbauld C, et al
    Immune Activation in Early Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab.
    Clin Cancer Res. 2017 Sep 26. pii: clincanres.2005.2017.
    PubMed     Text format     Abstract available
    
    
    
52. FENG Y, Wang X, Bajaj G, Agrawal S, et al
    Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2017;23:5394-5405.
    PubMed     Text format     Abstract available
    
    
    
53. GU L, Deng JZ, Roy S, Hammond PT, et al
    A Combination RNAi-Chemotherapy Layer-by-Layer Nanoparticle for Systemic Targeting of KRAS/P53 with Cisplatin to Treat Non-small Cell Lung Cancer.
    Clin Cancer Res. 2017 Sep 14. pii: clincanres.2186.2016.
    PubMed     Text format     Abstract available
    
    
    August 2017
54. OOKI A, Maleki Z, Tsay JJ, Goparaju CM, et al
    A panel of novel detection and prognostic methylated DNA markers in primary non-small cell lung cancer and serum DNA.
    Clin Cancer Res. 2017 Aug 29. pii: clincanres.1222.2017.
    PubMed     Text format     Abstract available
    
    
    
55. 
    Retraction: Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216.
    Clin Cancer Res. 2017;23:4523.
    PubMed     Text format    
    
    
    
56. ENGSTROM L, Aranda R, Lee M, Tovar EA, et al
    Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models.
    Clin Cancer Res. 2017 Aug 1. pii: clincanres.1192.2017.
    PubMed     Text format     Abstract available
    
    
    July 2017
57. SEN T, Tong P, Diao L, Li L, et al
    Targeting AXL and mTOR pathway overcomes primary and acquired resistance to WEE1 inhibition in small cell lung cancer.
    Clin Cancer Res. 2017 Jul 11. pii: clincanres.1284.2017.
    PubMed     Text format     Abstract available
    
    
    
58. GRAY JE, Heist RS, Starodub AN, Camidge DR, et al
    Therapy of Small-cell Lung Cancer (SCLC) With a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.0933.2017.
    PubMed     Text format     Abstract available
    
    
    
59. NISHINO M, Dahlberg SE, Adeni AE, Lydon C, et al
    Tumor response dynamics of advanced non-small-cell lung cancer patients treated with PD-1 inhibitors: Imaging markers for treatment outcome.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.1434.2017.
    PubMed     Text format     Abstract available
    
    
    
60. ADAMS DL, Adams DK, He J, Kalhor N, et al
    Sequential tracking of PD-L1 expression and RAD50 induction in circulating tumor and stromal cells of lung cancer patients undergoing radiotherapy.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.0802.2017.
    PubMed     Text format     Abstract available
    
    
    June 2017
61. MALCHERS F, Ercanoglu MS, Schutte D, Castiglione R, et al
    Mechanisms of primary drug resistance in FGFR1 amplified lung cancer.
    Clin Cancer Res. 2017 Jun 19. pii: clincanres.0478.2017.
    PubMed     Text format     Abstract available
    
    
    
62. WEINSTOCK C, Khozin S, Suzman D, Zhang L, et al
    U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2017 Jun 13. pii: clincanres.0540.2017.
    PubMed     Text format     Abstract available
    
    
    
63. JIN X, Chen Y, Chen H, Fei S, et al
    Evaluation of tumor-derived exosomal miRNA as potential diagnostic biomarkers for early stage non-small-cell lung cancer using next-generation sequencing.
    Clin Cancer Res. 2017 Jun 12. pii: clincanres.0577.2017.
    PubMed     Text format     Abstract available
    
    
    May 2017
64. CASCONE T, Xu L, Lin HY, Liu W, et al
    The HGF/c-MET pathway is a driver and biomarker of VEGFR-inhibitor resistance and vascular remodeling in non-small cell lung cancer.
    Clin Cancer Res. 2017 May 30. pii: clincanres.3216.2016.
    PubMed     Text format     Abstract available
    
    
    
65. JEONG J, Oh JH, Sonke JJ, Belderbos JSA, et al
    Modeling the Cellular Response of Lung Cancer to Radiation Therapy for a Broad Range of Fractionation Schedules.
    Clin Cancer Res. 2017 May 24. pii: clincanres.3277.2017.
    PubMed     Text format     Abstract available
    
    
    
66. LEE JMM, Lee MH, Garon E, Goldman JW, et al
    Phase I trial of intratumoral injection of CCL21 gene modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8+ T cell infiltration.
    Clin Cancer Res. 2017 May 3. pii: clincanres.2821.2016.
    PubMed     Text format     Abstract available
    
    
    April 2017
67. COOPER WA, Russell PA, Cherian M, Duhig EE, et al
    Intra- and Inter-Observer Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer (NSCLC).
    Clin Cancer Res. 2017 Apr 18. pii: clincanres.0151.2017.
    PubMed     Text format     Abstract available
    
    
    
68. LI AN, Yang J, Zhang XC, Zhang Z, et al
    Acquired MET Y1248H and D1246N mutations mediate resistance to MET inhibitors in non-small cell lung cancer.
    Clin Cancer Res. 2017 Apr 10. pii: clincanres.3273.2016.
    PubMed     Text format     Abstract available
    
    
    March 2017
69. TANG C, Welsh JW, de Groot P, Massarelli E, et al
    Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells.
    Clin Cancer Res. 2017;23:1388-1396.
    PubMed     Text format     Abstract available
    
    
    
70. BRANT R, Sharpe A, Liptrot T, Dry JR, et al
    Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors.
    Clin Cancer Res. 2017;23:1471-1480.
    PubMed     Text format     Abstract available
    
    
    
71. LIU Y, Balagurunathan Y, Atwater T, Antic S, et al
    Radiological Image Traits Predictive of Cancer Status in Pulmonary Nodules.
    Clin Cancer Res. 2017;23:1442-1449.
    PubMed     Text format     Abstract available
    
    
    
72. SCARBOROUGH HA, Helfrich BA, Casas-Selves M, Schuller AG, et al
    AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition.
    Clin Cancer Res. 2017;23:1531-1541.
    PubMed     Text format     Abstract available
    
    
    
73. KURZROCK R, Stewart DJ
    Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
    Clin Cancer Res. 2017;23:1137-1148.
    PubMed     Text format     Abstract available
    
    
    January 2017
74. DAMA E, Melocchi V, Dezi F, Pirroni S, et al
    An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers.
    Clin Cancer Res. 2017;23:62-72.
    PubMed     Text format     Abstract available
    
    
    July 2016
75. BALLARD P, Yates JW, Yang Z, Kim DW, et al
    Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
    Clin Cancer Res. 2016 Jul 19. pii: clincanres.0399.2015.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: